Profiling cellular bioenergetics, glutathione levels, and caspase activities in stomach biopsies of patients with upper gastrointestinal symptoms

Table 2 Measured biomarkers in gastric corpus vs antrum in the second cohort of patients (n = 23)

Patients	Age (yr)	GI presentation	Gender	Gastric corpus		Gastric antrum
				kc	GSH	kc	GSH
18	27	Liver lesion	F	0.11	357	0.12	378
19	71	Hypertension, diabetes, dyslipidemia, dyspepsia	M	0.13	627	0.16	379
20	22	Dyspepsia	M	0.13	366	0.25	331
21	18	Dyspepsia	F	0.14	319	0.19	260
22	30	Dyspepsia	M	0.16	733	0.21	853
23	34	Thyroidectomy, dyspepsia	F	0.14	449	0.18	408
24	24	Familial Mediterranean fever, dyspepsia	M	0.17	256	0.14	243
25	66	Diabetes, gastritis	M	0.15	243	0.12	317
26	69	Prostate cancer, aortic aneurysm, dyspepsia	M	0.22	269	0.13	470
27	22	Morbid obesity, dyspepsia	M	0.15	307	0.13	256
28	30	Dyspepsia	M	0.15	351	0.17	347
29	46	Obesity, dyspepsia	F	0.22	256	0.14	356
30	21	Dyspepsia	F	0.15	260	0.12	342
31	49	Hypertension, diabetes, ovarian, and cervical cancers, dyspepsia	F	0.18	202	0.10	104
32	44	Hypertension, diabetes, dyslipidemia, dyspepsia	F	0.18	180	0.17	166
33	34	Dyspepsia	F	0.20	218	0.11	256
34	18	Thalassemia major, s/p BMT, dyspepsia	F	0.15	219	0.12	193
35	81	GERD, esophagitis, hiatal hernia	M	0.19	279	0.11	219
36	62	Dyspepsia	F	0.28	258	0.19	554
37	40	Morbid obesity, dyslipidemia, chronic renal failure, dyspepsia	F	0.13	301	0.11	326
38	26	Data not available	F	0.30	305	0.18	177
39	39	Data not available	M	0.23	214	0.13	260
40	32	Data not available	F	0.21	166	0.12	211
mean ± SD	40.4 ± 19.8			0.18 ± 0.05	310 ± 135	0.15 ± 0.04	322 ± 155

kc, in μmol/L O₂ min^-1 mg^-1; GSH: Glutathione, in pmol/mg; s/p. BMT: Status post bone marrow transplantation; GERD: Gastroesophageal reflux disease; GI: Gastrointestinal.